Recent Updates
Recently added Catalysts
PCRX Positive Sentiment Score: 70/100

Pacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference

Key Takeaway: Pacira BioSciences, Inc. announced its participation in the 2024 RBC Capital Markets Global Healthcare Conference, scheduled for May 14, 2024. The company aims to provide a platform for discussing its innovative non-opioid therapies, such as EXPAREL, ZILRETTA, and iovera, which are designed to enhance pain management while minimizing reliance on opioids. A live audio stream of the event will be accessible on the company's website, along with a replay for two weeks post-event.

Market Sentiment Analysis

POSITIVE FACTORS

  • Pacira BioSciences is participating in a recognized healthcare conference, showing engagement with the investment community.
  • The company offers innovative non-opioid treatments, contributing positively to patient care.
  • Pacira is actively working to redefine opioid use, which aligns with current healthcare trends for safer pain management.

Full Press Release Details

TAMPA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference at 10:30 AM ET on Tuesday, May 14, 2024 in New York. Live audio of the event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.
Pacira BioSciences, Inc. (Nasdaq: PCRX) is committed to providing a non-opioid option to as many patients as possible to redefine the role of opioids as rescue therapy only. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and ioveraº®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.

Contact Data

Contact

With a Reader Account, it's easy to send email directly to the contact for this release. Sign up today for your free Reader Account!
Already have an account? Log in here.

Frequently Asked Questions

When is Pacira BioSciences' fireside chat scheduled?

The fireside chat is on May 14, 2024, at 10:30 AM ET.

How can I access the live audio of the event?

Visit the ‘Events’ page on Pacira's investor website to access the live audio.

What are Pacira's main non-opioid treatments?

Pacira offers EXPAREL®, ZILRETTA®, and ioveraº® for pain management.

What is the purpose of ioveraº®?

ioveraº® provides immediate, long-lasting pain relief through controlled cold therapy.

What is Pacira's mission regarding opioids?

Pacira aims to reduce the reliance on opioids by providing non-opioid options.

Last updated: May 7, 2024